Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Other
Sapropterin Dihydrochloride is a synthetic form of the naturally occurring cofactor tetrahydrobiopterin (BH4), indicated to reduce blood phenylalanine (Phe) levels in patients with BH4-responsive Phenylketonuria (PKU).
Name
Sapropterin Dihydrochloride
Raw Name
SAPROPTERIN DIHYDROCHLORIDE
Category
Other
Drug Count
4
Variant Count
21
Last Verified
February 17, 2026
RxCUI
1111018, 1111020, 1486687, 1486691, 1653217, 1653221, 2612671, 2611951, 2621237, 2712689, 2712691
UNII
RG277LF5B3
About Sapropterin Dihydrochloride
Sapropterin Dihydrochloride is a synthetic form of the naturally occurring cofactor tetrahydrobiopterin (BH4), indicated to reduce blood phenylalanine (Phe) levels in patients with BH4-responsive Phenylketonuria (PKU).
Detailed information about Sapropterin Dihydrochloride
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Sapropterin Dihydrochloride.
Sapropterin Dihydrochloride is a synthetic pharmaceutical formulation of the naturally occurring intracellular cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin, commonly abbreviated as BH4. It belongs to a specialized class of medications known as phenylalanine hydroxylase (PAH) activators. The primary therapeutic objective of Sapropterin Dihydrochloride is the management of hyperphenylalaninemia (HPA) in patients diagnosed with Phenylketonuria (PKU), a rare genetic metabolic disorder. PKU is characterized by a deficiency or defect in the enzyme phenylalanine hydroxylase, which is responsible for converting the essential amino acid phenylalanine (Phe) into tyrosine. Without sufficient PAH activity, phenylalanine accumulates to toxic levels in the blood and brain, potentially leading to severe intellectual disabilities, seizures, and behavioral issues.
Sapropterin Dihydrochloride was first granted approval by the U.S. Food and Drug Administration (FDA) in December 2007 under the brand name Kuvan. It represented a landmark shift in the treatment of PKU, offering the first pharmacological intervention to supplement the traditional, highly restrictive low-protein diet. It is important to note that not all patients with PKU respond to Sapropterin; it is specifically indicated for those whose PAH enzyme retains enough residual activity to be stimulated by exogenous (external) BH4 supplementation. Your healthcare provider will typically perform a response test to determine if the medication is effective for your specific genetic mutation before committing to long-term therapy.
To understand the mechanism of Sapropterin Dihydrochloride, one must understand the biochemistry of the phenylalanine hydroxylase (PAH) system. In a healthy individual, the PAH enzyme requires three components to function: the substrate (phenylalanine), molecular oxygen, and the cofactor tetrahydrobiopterin (BH4). Sapropterin is the synthetic equivalent of this BH4 cofactor.
At the molecular level, Sapropterin works through two primary mechanisms. First, it acts as a necessary 'helper' molecule that binds to the PAH enzyme, facilitating the chemical reaction that transforms phenylalanine into tyrosine. Second, in many patients with PKU, the genetic mutation causes the PAH enzyme to misfold or become unstable. Sapropterin acts as a 'pharmacological chaperone,' binding to the mutant enzyme and stabilizing its structure, which prevents it from being prematurely degraded by the cell. By increasing the stability and activity of the available PAH enzyme, Sapropterin enhances the body's natural ability to clear phenylalanine from the bloodstream. This allows some patients to increase their intake of natural protein while maintaining safe blood Phe levels, though it is rarely a total replacement for dietary management.
Understanding how the body processes Sapropterin Dihydrochloride is essential for optimizing its therapeutic effect. The pharmacokinetics of the drug are influenced significantly by administration timing and food intake.
Sapropterin Dihydrochloride is FDA-approved for a specific, narrow indication:
While not officially approved for other conditions, researchers have investigated its use in other disorders involving BH4 deficiency, such as certain types of neurotransmitter disorders and cardiovascular conditions where nitric oxide synthase (which also requires BH4) is dysfunctional. However, these uses remain experimental and are not standard clinical practice.
Sapropterin Dihydrochloride is available in several oral formulations to accommodate different age groups and preferences:
> Important: Only your healthcare provider can determine if Sapropterin Dihydrochloride is right for your specific condition. Regular blood monitoring is required to assess the drug's efficacy and safety.
The standard starting dose for Sapropterin Dihydrochloride in adults is typically 10 mg/kg of body weight, taken once daily. Based on the patient's response and blood phenylalanine (Phe) levels, healthcare providers may adjust the dose within a range of 5 mg/kg to 20 mg/kg per day. The goal of therapy is to maintain blood Phe levels within the range recommended by current clinical guidelines (typically 120–360 μmol/L). If blood Phe levels do not decrease after one month of treatment at the maximum dose of 20 mg/kg/day, the patient is generally considered a 'non-responder,' and the medication is typically discontinued.
Sapropterin Dihydrochloride is approved for use in pediatric patients of all ages, including neonates and infants.
Specific dosing adjustments for patients with renal (kidney) impairment have not been formally established in clinical trials. However, because the drug and its metabolites are primarily excreted by the kidneys, healthcare providers should exercise caution and monitor these patients closely for potential toxicity.
Sapropterin is primarily metabolized in the liver. While there are no specific dose adjustment guidelines for hepatic (liver) impairment, patients with significant liver dysfunction should be monitored closely, as the metabolism of BH4 may be altered.
Clinical studies of Sapropterin Dihydrochloride did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients. Dosing for elderly patients should be approached conservatively, usually starting at the low end of the dosing range.
If you miss a dose, take it as soon as you remember on the same day. However, if it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not take two doses at the same time to make up for a missed one.
Symptoms of an overdose may include significant headache, dizziness, or upper abdominal pain. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is generally supportive, focusing on managing symptoms.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or change your dietary protein intake without medical guidance.
In clinical trials, the most frequently reported side effects associated with Sapropterin Dihydrochloride were generally mild to moderate. These include:
> Warning: Stop taking Sapropterin Dihydrochloride and call your doctor immediately if you experience any of these.
The long-term use of Sapropterin Dihydrochloride is generally well-tolerated when monitored correctly. However, the primary long-term risk is the potential for nutritional deficiencies if the diet is not adjusted appropriately in response to the medication. Because Sapropterin allows for increased protein intake, patients must work closely with a metabolic dietitian to ensure they are receiving adequate vitamins and minerals. There is also a theoretical risk of affecting other BH4-dependent pathways, such as the synthesis of dopamine and serotonin, though clinical evidence of significant long-term neurotransmitter imbalance is currently lacking.
There are currently no FDA black box warnings for Sapropterin Dihydrochloride. However, the absence of a black box warning does not mean the drug is without risk. The most significant clinical warnings involve the risk of hypersensitivity and the necessity of frequent blood monitoring to avoid hypophenylalaninemia.
Report any unusual symptoms to your healthcare provider. Monitoring is the cornerstone of safe and effective PKU management.
Sapropterin Dihydrochloride is not a 'cure' for PKU. It is a therapeutic tool that must be used alongside a phenylalanine-restricted diet. Patients must continue to monitor their intake of high-protein foods (meat, fish, eggs, dairy, nuts, and legumes) as directed by their metabolic specialist. The drug's effectiveness can vary significantly between individuals based on their specific genetic mutations.
No FDA black box warnings for Sapropterin Dihydrochloride.
Effective management with Sapropterin Dihydrochloride requires a rigorous monitoring schedule:
Sapropterin Dihydrochloride is not generally known to cause significant impairment of motor skills or cognitive function. However, side effects like dizziness or headache can occur. Patients should ensure they know how the medication affects them before driving or operating heavy machinery.
There is no known direct chemical interaction between Sapropterin Dihydrochloride and alcohol. However, alcohol consumption can complicate the management of a PKU diet and may exacerbate gastrointestinal side effects like gastritis. It is best to discuss alcohol use with your healthcare provider.
If Sapropterin Dihydrochloride is discontinued, blood phenylalanine levels will likely return to their pre-treatment baseline within 1 to 2 weeks. There is no known 'withdrawal syndrome,' but patients must immediately revert to a stricter low-protein diet to prevent toxic Phe accumulation. Never stop taking the medication without consulting your metabolic team.
> Important: Discuss all your medical conditions with your healthcare provider before starting Sapropterin Dihydrochloride.
There are no drugs that are strictly 'contraindicated' (forbidden) for use with Sapropterin Dihydrochloride in the sense of causing immediate fatality. However, certain combinations are highly discouraged due to significant safety risks.
Sapropterin Dihydrochloride does not have many known interactions with common laboratory tests, but it is essential to inform the lab that you are taking a synthetic cofactor, as it may theoretically interfere with certain specialized assays for biogenic amines or pterins.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. The management of PKU is a delicate balance that can be disrupted by many substances.
There are very few absolute contraindications for Sapropterin Dihydrochloride, as it is a synthetic version of a natural substance. However, the following apply:
Relative contraindications require a careful risk-benefit analysis by a physician:
There is no well-documented cross-sensitivity between Sapropterin and other major drug classes. However, because the tablets contain ascorbic acid (Vitamin C), patients with extreme sensitivities to high-dose Vitamin C or specific dyes/fillers used in the manufacturing process should review the full ingredient list with their pharmacist.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to medications, before prescribing Sapropterin Dihydrochloride.
Managing PKU during pregnancy is critical. High maternal blood phenylalanine levels are teratogenic (harmful to the fetus) and can cause 'Maternal PKU Syndrome,' characterized by microcephaly (small head), intellectual disability, and congenital heart defects in the infant.
It is not known whether Sapropterin is excreted in human breast milk. However, because BH4 is a natural component of breast milk, and the primary goal is to maintain the mother's metabolic health, breastfeeding is usually not discouraged. The infant's blood Phe levels should be monitored if the mother is taking Sapropterin, especially if the infant also has PKU.
Sapropterin Dihydrochloride is approved for use in pediatric patients from birth onwards. It is one of the few medications with extensive safety data in neonates.
There is limited data on the use of Sapropterin in patients over age 65. Because PKU was only added to newborn screening programs in the 1960s, the population of older adults with treated PKU is currently small. In general, elderly patients should be monitored for renal function and potential interactions with medications for age-related conditions like hypertension or heart disease.
Since Sapropterin is eliminated by the kidneys, patients with a glomerular filtration rate (GFR) below 60 mL/min should be monitored more frequently. There are no specific guidelines for dialysis patients, and the drug's dialyzability is unknown.
Patients with significant liver disease (Child-Pugh Class B or C) may have impaired PAH activity, which could theoretically make the drug less effective. Close monitoring of blood Phe levels is the best way to manage these patients.
> Important: Special populations require individualized medical assessment and frequent monitoring by a metabolic specialist.
Sapropterin Dihydrochloride is a synthetic version of the naturally occurring (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4). It acts as a potent activator of the enzyme phenylalanine hydroxylase (PAH). In patients with PKU, PAH activity is deficient. Sapropterin binds to the PAH enzyme and serves as a necessary cofactor for the hydroxylation of phenylalanine to tyrosine. Furthermore, it acts as a molecular chaperone, stabilizing misfolded PAH proteins and increasing the effective concentration of the enzyme in the liver.
The primary pharmacodynamic effect of Sapropterin is the reduction of blood phenylalanine levels. This effect is dose-dependent. The onset of action is relatively rapid, with Phe levels typically beginning to drop within 24 hours of the first dose, though a full therapeutic response may take up to a month to evaluate. There is no evidence of tolerance development (loss of effect over time) as long as the underlying genetic response is present.
| Parameter | Value |
|---|---|
| Bioavailability | Increased significantly with food |
| Protein Binding | Not significantly bound to plasma proteins |
| Half-life | ~6.7 hours (range 3.9 to 17 hours) |
| Tmax | 3 to 4 hours |
| Metabolism | Primarily hepatic (oxidation/reduction) |
| Excretion | Renal (Urine) |
Sapropterin Dihydrochloride is classified as a Phenylalanine Hydroxylase (PAH) Activator. It is the only drug in this specific class, although other treatments for PKU, such as Pegvaliase (Palynziq), exist but work through a different mechanism (enzyme substitution).
Medications containing this ingredient
Common questions about Sapropterin Dihydrochloride
Sapropterin Dihydrochloride is primarily used to lower blood phenylalanine (Phe) levels in adults and children with a genetic disorder called Phenylketonuria (PKU). It is a synthetic form of a natural cofactor called BH4 that helps the enzyme phenylalanine hydroxylase work more effectively. By lowering Phe levels, the medication helps prevent the brain damage and neurological issues associated with PKU. It is important to note that it only works for patients who have 'BH4-responsive' PKU, which is determined through a clinical trial of the drug. It must always be used in combination with a special low-protein diet managed by a healthcare team.
The most common side effects reported by patients taking Sapropterin Dihydrochloride include headache, runny nose, sore throat, and cough. Some people also experience gastrointestinal symptoms such as nausea, vomiting, diarrhea, and upper stomach pain. These side effects are usually mild and often occur when first starting the medication or during a dose increase. In children, a common side effect is a low-grade fever or increased activity levels. If any of these symptoms become severe or persistent, you should contact your healthcare provider for a review of your treatment plan.
There is no known direct chemical interaction between Sapropterin Dihydrochloride and alcohol; however, caution is advised. Alcohol can irritate the stomach lining, which may worsen the risk of gastritis, a known side effect of Sapropterin. Additionally, many alcoholic beverages contain small amounts of protein or are consumed with high-protein snacks, which can make managing your blood phenylalanine levels more difficult. Alcohol can also impair your ability to strictly follow your required PKU diet. It is best to discuss your alcohol consumption with your metabolic specialist to ensure it does not interfere with your treatment goals.
Sapropterin Dihydrochloride is often considered necessary during pregnancy for women with PKU because maintaining low blood phenylalanine levels is crucial for the health of the developing baby. High Phe levels in a pregnant woman can cause 'Maternal PKU Syndrome,' leading to heart defects and intellectual disabilities in the infant. While there are no large-scale controlled studies in pregnant women, data from pregnancy registries suggest that the benefits of controlling Phe levels with Sapropterin usually outweigh the potential risks. Pregnant women should be monitored very closely by their metabolic team, often with weekly blood tests. Always consult your doctor if you are pregnant or planning to become pregnant.
Sapropterin Dihydrochloride begins to work relatively quickly, with changes in blood phenylalanine levels often detectable within 24 hours of the first dose. However, healthcare providers typically evaluate the full effectiveness of the drug over a period of up to four weeks. During this 'response test' period, you will have frequent blood tests while taking the maximum recommended dose (usually 20 mg/kg). If your Phe levels drop by at least 30% during this time, you are considered a responder. If there is no significant change after a month, the medication is usually deemed ineffective for your specific genetic mutation and will be stopped.
You should never stop taking Sapropterin Dihydrochloride suddenly without first consulting your healthcare provider. While there is no 'withdrawal' effect like those seen with some other medications, stopping the drug will cause your blood phenylalanine levels to rise rapidly, often returning to high, pre-treatment levels within a week. This can be dangerous if you do not immediately adjust your diet to be much more restrictive in protein. If you must stop the medication, your metabolic dietitian will need to help you transition back to a stricter diet to prevent toxic Phe accumulation in your brain.
If you miss a dose of Sapropterin Dihydrochloride, you should take it as soon as you remember on the same day, provided you take it with a meal. If you do not remember until the following day, do not take two doses to make up for the missed one. Instead, simply skip the missed dose and take your next scheduled dose at the usual time with your meal. Consistency is very important for maintaining stable blood Phe levels, so try to use reminders or pill organizers. If you miss multiple doses in a row, notify your healthcare provider, as your blood Phe levels may need to be checked.
Sapropterin Dihydrochloride itself is not known to cause weight gain as a direct physiological side effect. However, because the medication allows many patients to eat a wider variety of foods and more natural protein, some individuals may inadvertently increase their total calorie intake, which can lead to weight gain. It is important to work closely with a metabolic dietitian to ensure that as you add more protein to your diet, you are still maintaining a balanced and healthy caloric intake. If you notice unexpected weight changes, discuss them with your medical team to adjust your meal plan.
Sapropterin Dihydrochloride can interact with several types of medications, so you must inform your doctor of everything you are taking. Significant interactions occur with PDE-5 inhibitors (like Sildenafil), which can cause low blood pressure, and with Levodopa, which can affect dopamine levels and muscle control. Additionally, drugs that interfere with folate metabolism, such as Methotrexate or Trimethoprim, may make Sapropterin less effective. Most common medications like ibuprofen or allergy pills are generally safe, but always check with your pharmacist or doctor before starting anything new to ensure it won't interfere with your PKU management.
Yes, Sapropterin Dihydrochloride is available as a generic medication. The brand name version, Kuvan, was the only option for many years, but the FDA has since approved several generic versions in both tablet and powder forms. Generic versions are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. Choosing a generic can often reduce the out-of-pocket cost for patients and families. You should speak with your pharmacist or insurance provider to see if a generic version is available and appropriate for your prescription.